Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial

Journal:

The Lancet

Published:

2025-05-08

DOI:

10.1016/s0140-6736(25)00721-4

Affiliations:

8

Authors:

16

Go to article

Institutions	Authors	Share
Cleveland Clinic, United States of America (USA)	6.000000	0.38
NewAmsterdam Pharma B.V., Netherlands	6.000000	0.38
Monash University, Australia	1.000000	0.06
Johns Hopkins University (JHU), United States of America (USA)	1.000000	0.06
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.06
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	0.500000	0.03
Parkland Health and Hospital System, United States of America (USA)	0.500000	0.03

Interested in Cardiovascular Medicine and Haematology?